查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1726078

分子影像的全球市場，市場規模和佔有率的分析 - 成長趨勢與預測(2025年～2033年)

Molecular Imaging Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033
出版日期: | 出版商: Renub Research | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

分子影像市場趨勢及總結

預計2033年，全球分子影像市場規模將從2024年的79.6億美元增至123.6億美元，2025年至2033年的複合年增長率為5.01%。這得益於疾病早期診斷需求的不斷增長、影像診斷技術的創新以及癌症和神經系統疾病盛行率的不斷上升，而分子影像在精準診斷和個人化治療中發揮關鍵作用。

分子影像市場成長的推動因素

慢性病盛行率的不斷上升

癌症、心血管疾病和神經系統疾病等慢性病盛行率的不斷上升是分子影像產業發展的主要推動因素。此類疾病需要早期準確診斷，而分子成像透過在分子和細胞層面上可視化生物功能，實現了早期準確診斷。這些技術可以改善疾病的檢測、分期和監測，從而改善患者的預後，並增加對下一代影像技術的需求。每年有1800萬人死於心血管疾病，這些疾病會影響心臟和血管，導致心臟病發作、中風和心臟衰竭。每年約有900萬人死於癌症，400萬人死於氣喘和慢性阻塞性肺病等慢性呼吸道疾病，200萬人死於糖尿病。然而，疾病負擔和現代醫療保健的可近性分佈不均。

影像診斷的進步

隨著PET/CT和PET/MRI等混合影像模式的引入，影像診斷技術的不斷進步改變了診斷的可能性。這些進步使得影像解析度更高、靈敏度更高，並有可能在早期發現疾病。這些技術進步不僅提高了診斷的準確性，還增加了分子影像在個人化醫療中的應用，從而推動了市場成長。 2024年6月，Lantheus Holdings, Inc. 宣布收購了Life Molecular Imaging公司針對胃泌素釋放肽受體(GRPR)的RM2藥物的全球權利。這些權利包括臨床階段的放射治療藥物177Lu-DOTA-RM2和放射診斷藥物68Ga-DOTA-RM2。此次收購將拓寬Lantheus的研發管線，使其涵蓋乳癌和其他癌症，並專注於攝護腺癌。該交易包括3500萬美元的預付款，以及潛在的里程碑付款和特許權使用費。

研發創新

目前，公司正在投入大量資金進行研發，以尋找新的造影劑並增強現有的影像模式。這對於分子影像技術的進步至關重要，因為它有助於開發更有效率的診斷和治療方法。專注於研發將支持市場成長，並帶來一系列新的解決方案來填補臨床需求的空缺。據美國放射學會稱，總統2024財年預算大幅增加了對美國國家癌症研究所 (NCI) 的可自由支配資金，達到7.16億美元，比2023財年的撥款增加了5億美元。這筆資金將用於推進研究、預防、診斷和治療工作，這些工作都高度依賴放射學和影像技術。

分子影像市場面臨的課題

影像設備和程式成本高

先進分子影像設備和程序的高成本是市場擴張的主要障礙。高昂的購買和維護成本限制了這些技術的使用，尤其是在發展中國家和小型醫療中心。造影劑的成本和對技術人員的需求也推高了營運成本，阻礙了技術的廣泛應用。

監理與報銷課題

在複雜的監管環境中游刃有餘並獲得分子影像程式的報銷仍然具有課題性。嚴格的監管環境可能會阻礙新型成像劑和設備的批准和商業化。此外，不同地區不同的報銷政策也會影響分子影像服務的可近性和成本，進而影響市場滲透率。

本報告提供全球分子影像市場相關調查，成長推動因素與課題，各市場區隔的分析，主要企業的分析等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 成長促進因素
  • 課題

第5章 分子影像市場

  • 過去的市場趨勢
  • 市場預測

第6章 分子影像的市場佔有率分析

  • 各種模式
  • 各用途
  • 各最終用途
  • 各國

第7章 模式

  • 單一光子輻射斷層攝影(SPECT)
  • 正子輻射斷層攝影(PET)
  • 核磁共振光譜儀
  • 分子超音波成像
  • 其他

第8章 用途

  • 腫瘤
  • 心血管
  • 神經
  • 呼吸系統
  • 消化器官

第9章 最終用途

  • 醫院
  • 影像診斷中心
  • 研究機關

第10章 國家

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 比利時
    • 荷蘭
    • 土耳其
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 泰國
    • 馬來西亞
    • 印尼
    • 澳洲
    • 紐西蘭
  • 南美
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東·非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第11章 波特的五力分析

第12章 SWOT分析

第13章 主要企業的分析

  • GE HealthCare
  • Siemens Healthineers AG
  • Koninklijke Philips N.V.
  • Shimadzu Corp
  • United Imaging Healthcare Co., Ltd.
  • Bruker Corp
  • FUJIFILM Holdings Corp
  • Cubresa Inc.
簡介目錄

Molecular Imaging Market Trends & Summary

The Molecular Imaging Market is anticipated to grow to US$ 12.36 billion by 2033 from US$ 7.96 billion in 2024, at a CAGR of 5.01% during the period from 2025 to 2033. This is fueled by increasing demand for early disease diagnosis, technological innovations in imaging modalities, and rising incidence of cancer and neurological diseases, where molecular imaging plays a critical role in precision diagnosis and personalized treatment.

The report Molecular Imaging Market & Forecast covers by Modality (Single Photon Emission Computed Tomography, Psitron Emmission Tomography, Nuclear Magnetic Resonance Spectrometer, Molecular Ultrasound Imaging, Others), Application (Oncology, Cardiovascular, Neurology, Respiratory, Gastrointestinal), End Use (Hospitals, Diagnostic Imaging Centers, Research Institutes), Country and Company 2025-2033.

Molecular Imaging Market Outlooks

Molecular imaging is a cutting-edge biomedical technology that facilitates visualization, characterization, and measurement of biological functions at the molecular and cellular level within living systems. In contrast to conventional imaging technologies that merely concentrate on anatomical structures, molecular imaging yields extensive information regarding how tissues and organs work in real-time. It integrates imaging modalities like positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and optical imaging with molecular probes or biomarkers.

Molecular imaging is essential in the early disease detection and follow-up of conditions like cancer, cardiovascular disease, and neurological diseases like Alzheimer's and Parkinson's disease. It assists in assessing the effectiveness of a treatment by monitoring biological reactions at the molecular level. It also assists in drug discovery since researchers can monitor how new drugs interact with biological targets in living organisms. Its non-invasive character and capability to deliver accurate, functional information make molecular imaging a pillar of personalized medicine.

Growth Drivers in the Molecular Imaging Market

Increased Incidence of Chronic Diseases

The growing prevalence of chronic diseases like cancer, cardiovascular disease, and neurological conditions is a key growth driver for the molecular imaging industry. Such diseases require early and precise diagnosis, which molecular imaging makes possible through the visualization of biological functions at the molecular and cellular levels. Such a capability improves the detection, staging, and monitoring of disease, improving patient outcomes and driving demand for next-generation imaging technology. Every year 18 million individuals succumb to cardiovascular diseases that involve the heart and blood vessels and can result in heart attacks, stroke, or heart failure. Approximately 9 million individuals die annually from cancers, 4 million from chronic respiratory diseases like asthma or COPD, and 2 million from diabetes. But both disease burden and access to contemporary health care are disproportionately allocated.

Advances in Imaging Modalities

Ongoing advances in imaging modalities, with the introduction of hybrid imaging modalities such as PET/CT and PET/MRI, have transformed diagnostic potential. These advances provide images with greater resolution, increased sensitivity, and the potential to detect illnesses at earlier stages. These technological advances not only improve diagnostic precision but also increase the utilization of molecular imaging in personalized medicine, thus boosting market growth. June 2024, Lantheus Holdings, Inc. reported its acquisition of worldwide rights to Life Molecular Imaging's RM2, targeting the gastrin-releasing peptide receptor (GRPR). These include the clinical-stage radiotherapeutic 177Lu-DOTA-RM2 and the radiodiagnostic 68Ga-DOTA-RM2. The acquisition strengthens Lantheus' emphasis on prostate cancer and broadens its pipeline to breast and other cancers, with an upfront payment of $35 million plus possible milestone payments and royalties.

Innovation in Research and Development

Higher expenditure in research and development processes to identify new imaging agents and enhance current imaging methods is underway. It is vital for the development of molecular imaging, as it results in the creation of more efficient diagnostic methods and treatments. The focus on R&D provides a stream of new solutions, which supports growth in the market and fills gaps in clinical need. As per the America College of Radiology, The president's 2024 budget included a substantial increase in discretionary funding for the National Cancer Institute (NCI) to USD 716 million, a USD 500 million increase from the FY 2023 allocation. The funds are to be used to advance research, prevention, diagnosis, and treatment efforts, all of which rely extensively on radiology and imaging technology.

Challenges in the Molecular Imaging Market

High Cost of Imaging Equipment and Procedures

The high cost of advanced molecular imaging equipment and procedures is a major hindrance to market expansion. High acquisition and maintenance expenses restrict the use of these technologies, especially in developing countries and small healthcare centers. The cost of imaging agents and the requirement for skilled personnel also drive up operational costs, preventing widespread adoption.

Regulatory and Reimbursement Challenges

Working with the intricate regulatory environment and gaining reimbursement for molecular imaging procedures is still difficult. The strict regulatory environment can hold up the approval and commercialization of new imaging agents and devices. In addition, variable reimbursement policies between different regions can impact the availability and cost of molecular imaging services, which can influence market penetration.

Molecular Ultrasound Imaging Market

Molecular ultrasound imaging integrates conventional ultrasound methods with targeted contrast agents to image particular molecular markers in the body. Molecular ultrasound imaging is a non-invasive technique with real-time imaging and high spatial resolution, and it is worth its weight in gold for early disease detection and monitoring therapeutic interventions. Its low cost of entry and favorable safety profile over other imaging modalities make it increasingly popular in the clinical environment.

Oncology Molecular Imaging Market

In cancer, molecular imaging is a central component of early detection, staging, and monitoring of cancer. Modalities such as PET and SPECT allow visualization of tumor metabolism and receptor expression and thus insight into tumor biology. Such information is invaluable for choosing the right therapies, evaluating treatment response, and detecting recurrences, thus enhancing patient management and outcomes.

Neurology Molecular Imaging Market

Molecular imaging plays a crucial role in diagnosing and managing neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy. By visualizing distinct neurotransmitter systems and pathological protein accumulations, these imaging techniques enable early diagnosis and monitoring of disease progression. This ability fosters a greater understanding of neurological disease and aids in the creation of targeted therapeutics.

Respiratory Molecular Imaging Market

Molecular imaging is supporting the evaluation of diseases such as chronic obstructive pulmonary disease (COPD), asthma, and lung cancer in respiratory medicine. Molecular imaging helps in imaging inflammatory processes, ventilation-perfusion mismatches, and tumor metabolism. All of this information guides clinicians to tailor treatment regimens, follow the therapeutic responses, and enhance the outcomes of the patients.

Molecular Imaging Hospitals Market

Hospitals are the first adopters of molecular imaging technologies because of their complete diagnostic and therapeutic facilities. Incorporation of molecular imaging in hospitals improves diagnostic accuracy, informs treatment planning, and enables personalized medicine strategies. Multidisciplinary teams and advanced infrastructure available in hospitals enable effective use of these imaging modalities.

Molecular Imaging in Research Institutes

Research institutes utilize molecular imaging to study mechanisms of disease, assess emerging treatments, and generate new imaging probes. The institutes are significant players in expanding the field by engaging in preclinical and clinical investigations that directly guide clinical care. Research institutes working together with industry partners are at the heart of driving innovation and shaping advances in molecular imaging technology.

United States Molecular Imaging Market

The United States is a large market for molecular imaging, with high incidence of chronic diseases, sophisticated healthcare infrastructure, and high research and development investment. The availability of top imaging technology firms and academic institutions encourages innovation and uptake of advanced imaging modalities. Favorable regulatory environments and reimbursement policies also encourage market growth. November 2024, United Imaging installed the world's first uMI Panvivo PET/CT at Pueblo Medical Imaging in Nevada, USA. The next-generation platform boasts a best-in-class NEMA spatial resolution of 2.9 mm* and an effective sensitivity of 181 cps/kBq. Equipped with its AI-based 3D camera technology, the uMI Panvivo brings precision and care to all.

Germany Molecular Imaging Market

Germany's molecular imaging market is marked by strong healthcare infrastructure, high focus on medical research, and positive reimbursement policies. The precision medicine and early disease detection focus of the country facilitates the uptake of advanced imaging technologies. Academic-industry collaborations help in the development and deployment of innovative imaging solutions. United Imaging has deployed its innovative molecular imaging technology in Germany, partnering with Medical Imaging Electronics (MiE). The Kliniken Essen-Mitte Evang and Nukmed are now equipped with the uMI 550 digital PET/CT system, a cutting-edge system.

India Molecular Imaging Market

The molecular imaging market in India is growing, supported by growing healthcare consciousness, rising chronic disease incidence, and increasing investments in healthcare infrastructure. Government policies promoting diagnostic ability and access to advanced medical technologies are driving market expansion. The emergence of affordable imaging solutions optimized for the Indian populace is also driving market growth. May 2025, Mahajan Imaging & Labs has inaugurated North India's first 128-Slice Digital PET-CT - Omni Legend by GE HealthCare, along with a state-of-the-art pathology lab in Gurugram. This new center is a major step forward in integrated cancer care and diagnostics for Delhi NCR.

Saudi Arabia Molecular Imaging Market

Saudi Arabia is experiencing growth in the molecular imaging market because of the increasing burden of chronic diseases, government investment in healthcare modernization, and initiatives to improve diagnostic capabilities. The Vision 2030 initiative of the country focuses on the development of sophisticated healthcare services, including the implementation of cutting-edge imaging technologies. Partnerships with global players and investments in health infrastructure facilitate the growth of the market. December 2024, King Abdulaziz University (KAU) has initiated a groundbreaking Alzheimer's disease diagnosis service at its Molecular Imaging Center (I-One) via Wadi Jeddah. This service is provided using combined Positron Emission Tomography and Magnetic Resonance Imaging (PET/MRI), making it the first of its nature in Saudi Arabia.

Molecular Imaging Market Segmentation

Modality

  • Single Photon Emission Computed Tomography
  • Psitron Emmission Tomography
  • Nuclear Magnetic Resonance Spectrometer
  • Molecular Utrasound Imaging
  • Others

Application

  • Oncology
  • Cardiovascular
  • Neurology
  • Respiratory
  • Gastrointestinal

End Use

  • Hospitals
  • Diagnostic Imaging Centers
  • Research Institutes

Countries

North America

  • United States
  • Canada

Europe

  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Belgium
  • Netherlands
  • Turkey

Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • Thailand
  • Malaysia
  • Indonesia
  • Australia
  • New Zealand

Latin America

  • Brazil
  • Mexico
  • Argentina

Middle East & Africa

  • Saudi Arabia
  • UAE
  • South Africa

All companies have been covered with 4 Viewpoints

  • Overview
  • Key Persons
  • Recent Development & Strategies
  • Revenue Analysis

Key Players Analysis

  • GE HealthCare
  • Siemens Healthineers AG
  • Koninklijke Philips N.V.
  • Shimadzu Corp
  • United Imaging Healthcare Co., Ltd.
  • Bruker Corp
  • FUJIFILM Holdings Corp
  • Cubresa Inc.

Table of Contents

1. Introduction

2. Research Methodology

  • 2.1 Data Source
    • 2.1.1 Primary Sources
    • 2.1.2 Secondary Sources
  • 2.2 Research Approach
    • 2.2.1 Top-Down Approach
    • 2.2.2 Bottom-Up Approach
  • 2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. Molecular Imaging Market

  • 5.1 Historical Market Trends
  • 5.2 Market Forecast

6. Molecular Imaging Market Share Analysis

  • 6.1 By Modality
  • 6.2 By Application
  • 6.3 By End Use
  • 6.4 By Countries

7. Modality

  • 7.1 Single Photon Emission Computed Tomography
  • 7.2 Psitron Emmission Tomography
  • 7.3 Nuclear Magnetic Resonance Spectrometer
  • 7.4 Molecular Utrasound Imaging
  • 7.5 Others

8. Application

  • 8.1 Oncology
  • 8.2 Cardiovascular
  • 8.3 Neurology
  • 8.4 Respiratory
  • 8.5 Gastrointestinal

9. End Use

  • 9.1 Hospitals
  • 9.2 Diagnostic Imaging Centers
  • 9.3 Research Institutes

10. Countries

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
  • 10.2 Europe
    • 10.2.1 France
    • 10.2.2 Germany
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Belgium
    • 10.2.7 Netherlands
    • 10.2.8 Turkey
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Thailand
    • 10.3.6 Malaysia
    • 10.3.7 Indonesia
    • 10.3.8 Australia
    • 10.3.9 New Zealand
  • 10.4 Latin America
    • 10.4.1 Brazil
    • 10.4.2 Mexico
    • 10.4.3 Argentina
  • 10.5 Middle East & Africa
    • 10.5.1 Saudi Arabia
    • 10.5.2 UAE
    • 10.5.3 South Africa

11. Porter's Five Forces Analysis

  • 11.1 Bargaining Power of Buyers
  • 11.2 Bargaining Power of Suppliers
  • 11.3 Degree of Rivalry
  • 11.4 Threat of New Entrants
  • 11.5 Threat of Substitutes

12. SWOT Analysis

  • 12.1 Strength
  • 12.2 Weakness
  • 12.3 Opportunity
  • 12.4 Threat

13. Key Players Analysis

  • 13.1 GE HealthCare
    • 13.1.1 Overview
    • 13.1.2 Key Persons
    • 13.1.3 Recent Development & Strategies
    • 13.1.4 Revenue Analysis
  • 13.2 Siemens Healthineers AG
    • 13.2.1 Overview
    • 13.2.2 Key Persons
    • 13.2.3 Recent Development & Strategies
    • 13.2.4 Revenue Analysis
  • 13.3 Koninklijke Philips N.V.
    • 13.3.1 Overview
    • 13.3.2 Key Persons
    • 13.3.3 Recent Development & Strategies
    • 13.3.4 Revenue Analysis
  • 13.4 Shimadzu Corp
    • 13.4.1 Overview
    • 13.4.2 Key Persons
    • 13.4.3 Recent Development & Strategies
    • 13.4.4 Revenue Analysis
  • 13.5 United Imaging Healthcare Co., Ltd.
    • 13.5.1 Overview
    • 13.5.2 Key Persons
    • 13.5.3 Recent Development & Strategies
    • 13.5.4 Revenue Analysis
  • 13.6 Bruker Corp
    • 13.6.1 Overview
    • 13.6.2 Key Persons
    • 13.6.3 Recent Development & Strategies
    • 13.6.4 Revenue Analysis
  • 13.7 FUJIFILM Holdings Corp
    • 13.7.1 Overview
    • 13.7.2 Key Persons
    • 13.7.3 Recent Development & Strategies
    • 13.7.4 Revenue Analysis
  • 13.8 Cubresa Inc.
    • 13.8.1 Overview
    • 13.8.2 Key Persons
    • 13.8.3 Recent Development & Strategies